Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Targeted Therapeutics in Melanoma

Buch | Hardcover
378 Seiten
2011
Humana Press Inc. (Verlag)
978-1-61779-406-3 (ISBN)

Lese- und Medienproben

Targeted Therapeutics in Melanoma -
CHF 224,65 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.

The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics.
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.



The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.



This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Molecular targets and subtypes in melanoma.- Melanoma genomics.- Predictive biomarkers as a guide to future therapy selection in melanoma.- KIT as a therapeutic target for melanoma.- Targeted inhibition of B-Raf.- The notch and B-catenin pathways.- STAT3 and Src signaling in melanoma.- Targeting the mTOR, PI3K and AKT pathways in melanoma.- Targeting apoptotic pathways in melanoma.- Anti-angiogenesis therapy in melanoma.- Melanoma antigens recognized by T lymphocytes.- Melanoma vaccines.- Adoptive cell therapy for the treatment of metastatic melanoma.- Anti-CTLA-4 monolonal antibodies.- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies.- Treatment of melanoma with agonist immune co-stimulatory agents.- Novel cytokines for immunotherapy of melanoma.- Modulating the tumor microenvironment.

Reihe/Serie Current Clinical Oncology
Zusatzinfo XIV, 378 p.
Verlagsort Totowa, NJ
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Dermatologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
ISBN-10 1-61779-406-6 / 1617794066
ISBN-13 978-1-61779-406-3 / 9781617794063
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Differentialdiagnostik und Therapie bei Kindern und Jugendlichen

von Peter Höger

Buch (2022)
Thieme (Verlag)
CHF 191,00
richtig verschreiben – individuell therapieren

von Claus Garbe; Holger Reimann

Buch (2023)
Thieme (Verlag)
CHF 99,40